Canon, Kyoto Univ. to Study Autologous iPS Cells
Newsfrom JapanEconomy Science Technology
Tokyo, Aug. 1 (Jiji Press)--Canon Inc. <7751> said Thursday it and a team of a Kyoto University laboratory have started joint research on induced pluripotent stem, or iPS, cells produced from a patient's own cells.
The autologous cells are believed to reduce risks such as rejection reactions.
Canon and the team of the university's Center for iPS Cell Research and Application aim to produce high-quality iPS cells at a low cost through the use of Canon's technologies, such as diagnostic imaging.
Currently, iPS production is considered challenging, mainly due to the high cost of testing.
The company has been trying to expand its medical business, one of its core operations, and it is considering entering into the field of regenerative medicine.
[Copyright The Jiji Press, Ltd.]